SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available later that day.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers…
LEHI, Utah and LOUISVILLE, Ky., April 7, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY),…
DEMOGRAPHIC FINDINGS SHOW CONTINUED GROWTH, TREMENDOUS DIVERSITY AND DEEP CONNECTIONS TO ISRAEL AND JEWISH LIFE…
CHICAGO, April 7, 2025 /PRNewswire/ -- Shapiro+Raj, the #1 Strategic and #12 Most Innovative Insights…
COLUMBUS, Ohio, April 7, 2025 /PRNewswire/ -- CAS, a division of the American Chemical Society…
LOS ANGELES, April 7, 2025 /PRNewswire/ -- After years of navigating the complexities of payer systems,…